Casper Corey
Department of Medicine, Division of Infectious Disease, University of Washington School of Medicine, and The Program in Infectious Disease, Fred Hutchinson Cancer Research Center, Seattle, WA 98122, USA.
Br J Haematol. 2005 Apr;129(1):3-17. doi: 10.1111/j.1365-2141.2004.05311.x.
Fifty years ago, Dr Benjamin Castleman first described the unusual lymphoproliferative disorder that now bears his name. Over the subsequent decades, astute clinical and pathologic observations coupled with clever molecular biologic research have increased our understanding of the aetiology of Castleman disease (CD). This article proposes three broad CD variants based on both distinctive histopathology and clinical behaviour. The pivotal roles of infection with human herpesvirus 8 and interleukin-6 production in the development of CD are emphasized. Finally, the natural history of CD and the myriad of therapeutic options are reviewed in the context of a unified model of CD pathophysiology, and continued areas of uncertainty are discussed.
五十年前,本杰明·卡斯尔曼博士首次描述了这种如今以他的名字命名的罕见淋巴增生性疾病。在随后的几十年里,敏锐的临床和病理观察以及巧妙的分子生物学研究增进了我们对卡斯尔曼病(CD)病因的理解。本文基于独特的组织病理学和临床行为提出了三种主要的CD变体。强调了人类疱疹病毒8感染和白细胞介素-6产生在CD发展中的关键作用。最后,在CD病理生理学统一模型的背景下回顾了CD的自然病程和众多治疗选择,并讨论了仍存在不确定性的领域。